Company intelligence / Profile preview

Novvae Pharmaceuticals

Berwyn, Pennsylvania, USA

Ownership: Private
Development stage: Other

Overview

Novvae Pharmaceuticals is a wholly-owned subsidiary of Virpax Pharmaceuticals, established in 2023 to focus exclusively on the development and commercialization of over-the-counter (OTC) product candidates. The company's lead asset is AnQlar, a prophylactic antiviral nasal spray designed to inhibit viral replication of influenza and SARS-CoV-2 using a chitosan-based nanoparticle dispersion. Novvae also manages Epoladerm, a topical diclofenac spray film for osteoarthritis pain management. By separating these non-prescription assets into a dedicated entity, the parent company aims to streamline its focus on its prescription (Rx) pain management pipeline.

Therapeutic areas: NeurologyRheumatologyInfectious Diseases
Modalities: NanoparticleNasal sprayTopical spray
Industry: Biotech

Beyond the preview

Go deeper on Novvae Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novvae Pharmaceuticals.

Explore the full profile